Fidia S.p.a.

Lifegroup S.p.a.

Epitech Group S.r.l.

Innovet Italia S.r.l.

Epitech Group S.p.a.

Consiglio Nazionale Delle Richerche

Epitech S.p.a.

Francesco Della Valle

Aurelio Romeo

Maria Federica Della Valle

Silvana Lorenzi

Gabriele Marcolongo

Gabriella Calderini

Lanfranco Callegaro

Alessandro Rastrelli

Salvatore Cuzzocrea

Vincenzo Di Marzo

Roberto Cerini

Luciano De Petrocellis

Alberta Leon

Chiara Gomiero

Federica Della Valle

Vito Safina

Cristina Comelli

Carla Ghelardini

Gino Toffano

Vittorio Crescenzi

Raffaele Migliaccio

Alessandro Negro

Lauro Galzigna

Giuseppe D'Agostino

Roberto Russo

Giuseppe Esposito

Sebastiano Mangiafico

Tiziana Bisogno

Daniel J Iosa

Antonio Calignano

Jacobus C Samson

Michela Rampazzo

Sofia Parrasia

Vanni Canton

Rosaria Meli

Sabatino Maione

Sonia Laneri

Carmine Ostacolo

Annalisa Noce

Dominique Melck

Giuliano Claps

Lorenzo Di Cesare Manelli

Antonia Sacchi

Stefania Petrosino

Barbara Costa

Diana Tronino

Daniele Grassi

Claudia Cristiano

Raffaele Capasso

Ester Pagano

Francesca Borrelli

Gianpiero Ravagnan

Angelo Antonio Izzo

Giuseppe D'agostino

Barbara Romano

The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

Method for the treatment of COVID-19 infections with palmitoylethanolamide

It is the object of the present invention a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide for the control of the inflammatory and/or neuropathic pain of various origin. In particular, the present invention relates to a pharmaceutical composition comprising palmitoylethanolamide (PEA and L-acetylcarnitine (LAC), optionally with in addition an antioxidant compound such as a polyphenol, alpha-lipoic acid, and L-acetylcysteine.

Pharmaceutical composition comprising palmitoylethanolamide and L- Acetylcarnitine

A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages): A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.

Composition of acylethanolamides from olive oil fatty acids

Described herein is a composition based on N-palmitoyl-ethanolamide and Rutin in co-micronized form. In particular, a composition includes a mixture of palmitoyl-ethanolamide (PEA) and Rutin in co-micronized form in which the PEA/Rutin ratio is between 10:1 and 1:1. Pharmaceutical formulations for the treatment of humans and animals are also described. The composition is useable for the treatment of diseases of arteries and arterioles.

Composition of N-palmitoyl-ethanolamide and Rutin in co-micronized form

The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin. In particular, the present invention relates to N-palmitoyl-D-glucosamine in a micronized or co-micronized form with Curcumin. Such a product can be formulated in human or veterinary pharmaceutical compositions, dietetic products, food supplements, or foods for special medical purposes (FSMP), or in feeds, or nutritional supplements for animals for the treatment of chronic systemic inflammatory diseases, in humans and animals, resulting from dysfunctions of epithelia and synovial membranes.

N-palmitoyl-D-glucosamine in a micronized form

Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.

Use of a combination of Adelmidrol and hyaluronic acid in the treatment of pain caused by osteoarthritis and epithelial dysfunctions

A method of controlling the inflammatory and/or neuropatic pain of various origins by administering a pharmaceutical composition containing palmitoylethanolamide, to a human or animal patient. In particular, the present invention relates to the administration of a pharmaceutical composition comprising palmitoylethanolamide (PEA) and L-acetylcarnitine (LAC), optionally in addition with an antioxidant compound, such as a polyphenol, alpha-lipoic acid, or L-acetylcysteine to a patient.

Method of treating neuropathic pain with a synergistic pharmaceutical composition comprising palmitoylethanolamide and L-acetylcarnitine

Described herein are pharmaceutical compositions for human or animal use containing N-palmitoylethanolamide as an analgesic in combination with opioids. In particular, the compositions include palmitoylethanolamide in non-micronized form, in micronized form (PEA-m), in ultra-micronized form (PEAum) or mixtures thereof, for use in humans or animals in combination with an opioid in the treatment of pain conditions, wherein said palmitoylethanolamide is administered separately, sequentially, or in combination with said opioid.

Using palmitoylethanolamide in combination with opioids

It is the object of the present invention a composition containing an N-acyl-ethanolamine in a solubilized form, particularly a solution for ophthalmic, intra-articular or intravesical use. Particularly, the present invention relates to a water-soluble composition comprising one or more N-acylethanolamines (NAE) in the form of an inclusion complex in methyl-beta-cyclodextrin (M&#x3b2;CD).

Ophthalmic, intra-articular or intravesical preparations containing N-acyl-ethanolamines

The synthesis of a series of Polyethylene glycol conjugates (esters and carbonates) of PEA and its analogous acylethanolamides, have higher water solubility and good hydrophilic/lipophilic balance, resulting in (i) improved accumulation in tissues (particularly skin and mucosae), (ii) prolonged release, and (iii) increased bioavailability. Improvement of PEA and analogous acylethanolamides levels in the tissues&#x2014;particularly in the skin and mucosae&#x2014;and their prolonged release is due to the improved bioavailability of related conjugates. Conjugates are able to extend the time frame in which PEA and analogous acylethanolamides exert their pharmacological effects.

Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides

The present invention regards compositions and methods for the modulation of amidases capable of hydrolyzing N-acylethanolamines useable in the therapy of inflammatory diseases. In particular, the present invention regards a compound of general formula (I): enantiomers, diastereoisomers, racemes and mixtures, polymorphs, salts, solvates thereof, wherein: (a) R is a linear alkyl radical having 13 to 19 carbon atoms or alkenyl radical having 13 to 19 carbon atoms carrying a double bond; (b) X is 0 or S; (c) Y is a 2 or 3 carbon atom alkylene residue, optionally substituted with one or two groups equal or different from each other and selected from among the group consisting of: &#x2014;CH, &#x2014;CHOH, &#x2014;COOCH, &#x2014;COOH. Y may preferably be: &#x2014;CH&#x2014;CH&#x2014;, &#x2014;CH&#x2014;CH&#x2014;CH&#x2014;, CH(CH)&#x2014;CH&#x2014;, &#x2014;CH&#x2014;CH(CH)&#x2014;, &#x2014;CH&#x2014;C(CH)&#x2014;, &#x2014;CH&#x2014;CH(CHOH)&#x2014;, &#x2014;CH&#x2014;C((CHOH))&#x2014;, &#x2014;CH&#x2550;CH&#x2014;, &#x2014;CH&#x2014;CH(COOCH)&#x2014;, &#x2014;CH&#x2014;CH(COOH)&#x2014;, for use as a medicine. 

Compositions and methods for the modulation of specific amidases for N-acylethanolamines for use in the therapy of inflammatory diseases

A therapy for renal diseases, in particular renal diseases, which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, palmitoylethanolamide and diethanolamide of fumaric acid are used in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution.

Use of amides of mono- and dicarboxylic acids in the treatment of renal diseases

A therapy for renal diseases characterized by alterations of the kidney function, such as Chronic Kidney Disease (CKD), acute and chronic renal impairment, and renal diseases that develop in diabetic patients or in patients who underwent an anticancer chemotherapic treatment with a platinum derivative. The invention is a combination of compounds selected from mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol, and compounds selected from Silymarin, derivatives thereof or conjugates or complexes thereof, for use in the treatment of renal diseases. The mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or of a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol and said Silymarin, derivatives thereof or conjugates or complexes thereof are formulated for a separate, sequential, concomitant administration or in admixture, also in a co-micronized or co-ultra-micronized form.

Combined use of amides of mono- and dicarboxylic acids and silymarin in the treatment of renal diseases

The present invention relates to a composition for pharmaceutical or veterinary use, comprising palmitoylethanolamide. In particular, the present invention relates to a pharmaceutical composition for human or veterinary use, containing a therapeutically efficient amount of palmitoylethanolamide in the ultra-micronized form, wherein more than 90% by weight of palmitoylethanolamide has particle sizes lower than 6 microns, together with pharmaceutically acceptable excipients.

Compositions containing ultra-micronized palmitoyl-ethanolamide

The present invention relates to topical preparations containing N-palmitoyl-vanillamide having hyperalgesic activity. In particular, the invention relates to N-palmitoyl-vanillamide for use in the treatment of pathologies selected from: post-herpetic neuralgia, neuralgia of trigeminus, occipital neuralgia, dental neuralgia, glottopharyngeal neuralgia, uremic neuralgia, diabetic neuralgia, headache of different origin, neuropathic itch, neurogenic itch, uremic itch, vulvodinia, vulvar vestibulitis, ano-rectal pain and itch, balano-preputial pain and itch, painful urogenital disorders of dogs and cats, psoriasis-associated pruritus and pain, itching skin diseases (e.g. atopic dermatitis) in the human and veterinary field, muscular pain, pain of the tendon, osteoarthritis associated pain in humans, dogs and cats; painful eye diseases in the human and veterinary field, inflammatory pathologies of the oral cavity in the human and veterinary field.

Pharmacological preparation for topical use containing N-palmitoyl-vanillamide

Growing community of inventors

Padova, Italy

Francesco Della Valle